Covered recipient · General Payments record
KAITLYN CONWAY DULSKI
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2022–2024
$893.62
- Reported across 42 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $310.37 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $63.86 | 2 |
| Corium, Inc. | $58.71 | 3 |
| Acerta Pharma LLC | $56.02 | 3 |
| Lundbeck LLC | $40.87 | 2 |
| Axsome Therapeutics, Inc. | $20.41 | 1 |
| Novo Nordisk AS | $18.23 | 1 |
| GlaxoSmithKline, LLC. | $18.09 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.45 | 1 |
| Exact Sciences Corporation | $16.73 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $32.01 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107047308 | CMS |
| ABBVIE INC. | $31.85 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107047310 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.35 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104213075 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.86 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105815481 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.81 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104222847 | CMS |
| Axsome Therapeutics, Inc. | $20.41 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148373828 | CMS |
| Corium, LLC | $20.25 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100096823 | CMS |
| Corium, LLC | $5.12 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100132506 | CMS |
| Corium, LLC | $33.34 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100071645 | CMS |
| Exact Sciences Corporation | $16.73 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114437991 | CMS |
| GlaxoSmithKline, LLC. | $18.09 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116702819 | CMS |
| Lundbeck LLC | $21.74 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146016024 | CMS |
| Lundbeck LLC | $19.13 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146016026 | CMS |
| Novo Nordisk Inc | $18.23 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100635167 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.45 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137736986 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.